cytokine release syndrome, Jill O’Donnell-Tormey, Kymriah, Novartis

CAR-T Cell therapy could be made safer and more widely available with a few adjustments

March 2022: A revolutionary approach to CAR-T Cell therapy has the potential to overturn what has become a medical axiom: that the treatment's remarkable effect on tumours comes at the expense of substantial hazards to patient saf..

CAR T Cell immunotherapy, CAR T Technology, CAR T Therapy, Clinical trials

CAR-T therapy, CAR-T technology, what are CAR-T cell immunotherapy ? CAR-T treatment cost, latest CAR-T clinical trial recruitment

March 2022: CAR-T therapy, CAR-T technology, what are CAR-T cell immunotherapy ? CAR-T treatment price, cost, the latest CAR-T clinical trial recruitment information summary. The concept of boron neutron capture therapy has been ..

BCMA, CARVYKTI, ciltacabtagene autoleucel, immunomodulatory agent, Janssen Biotech, proteasome inhibitor

Ciltacabtagene autoleucel is approved for relapsed or refractory multiple myeloma

March 2022: After four or more prior lines of therapy, including a proteasome inhibitor (PI), an immunomodulatory agent (IMiD), and an anti-CD38 monoclonal antibody, the Food and Drug Administration has approved ciltacabtagene au..

Study suggest CAR T-Cell therapy effective as first line treatment for high risk large B-cell lymphoma

March 2022: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR T-cell therapy), is a safe and effective first-line therapy for patients wit..

Effectiveness of CAR T-Cell therapy against high risk large B-Cell lymphoma

Dec 2020: The University of Texas MD Anderson Cancer Center researchers discovered that axi-cel, an autologous anti-CD19 chimeric antigen receptor (CAR) T cell therapy, is a safe and effective first-line therapy for patients with ..

CAR - T Cell therapy

CAR T-Cell therapy for childhood brain tumor

Dec 2021: CAR T-Cell therapy is currently approved for some forms of leukemia, lymphoma, and multiple myeloma. Researchers have now also developed the corresponding GD2 CAR T-cell therapy for the treatment of neuroblastoma, i.e., ..

China, Chongqing, Professor Qian Cheng, University of Pennsylvania

Patient in China achieves complete remission from leukemia after CAR T-Cell therapy

Feb 2022: In China, a patient whose life was on the verge of ending was entirely healed of leukaemia thanks to CAR T-cell therapy, which stimulated the immune system. All cancer cells vanished swiftly in the first study of its kin..

CAR - T Cell therapy, CAR T, CAR T Cell therapy in China, CAR T-Cell, China, Treatment in China

China-based CAR-T Cell therapy achieves breakthrough clinical trial results

June 2016: Professor Huang He of Zhejiang University's First Affiliated Hospital presented the outcomes of 10 clinical cases, including CAR-T cell therapy for leukaemia treatment, at the 2016 Haematogenic Immunity Summit in Hangz..

CAR-T cells, chimeric antigen receptors, China, China CAR T therapy, Chongqing

CAR T-Cell therapy saves leukemia patient in China

Feb 2022: A 12-year-old girl from southwest China's Chongqing Municipality was saved by an unconventional therapy instead of chemotherapy or hematopoietic stem cell transplantation.Yi Mengdie has a seven-month medical history and ..

Abecma, B-cell maturation antigen, chimeric antigen receptor, idecabtagene vicleucel, proteasome inhibitor, refractory multiple myeloma

The FDA has approved idecabtagene vicleucel for the treatment of multiple myeloma

August 2021: The Food and Drug Administration approved idecabtagene vicleucel (Abecma, Bristol Myers Squibb) for the treatment of adult patients with relapsed or refractory multiple myeloma after four or more prior lines of therap..